he board of directors of Medtronic plc (NYSE: MDT) today approved a 13 percent increase in its quarterly cash dividend, raising the quarterly amount to $0.43 per ordinary share. This would translate into an annual amount of $1.72 per ordinary share. Today’s announcement marks the 39th consecutive year of an increase in the dividend payment for Medtronic, a constituent of the S&P 500 Dividend Aristocrats index. Including today’s increase, Medtronic’s dividend per share has nearly quadrupled over the past decade and has grown at an 18 percent compounded annual growth rate over the past 39 years. read more
The World Stroke Organization (WSO) today announced a global partnership with Medtronic plc (NYSE:MDT) to increase stroke awareness through several initiatives. The two organizations will work together to educate, raise awareness and support effective management of patients who have strokes.
The partnership, announced at the 2016 Annual Scientific Session of the Chinese Stroke Association (CSA) and Tiantan International Stroke Conference (TISC) in Beijing, will focus on continued growth of stroke awareness through the Stroke is Treatable World Stroke Day campaign; implementation of the WSO’s new global stroke services guidelines: The Roadmap to Delivering Quality Stroke Care; and, supporting WSO’s global clinical educational programs including the World Stroke Academy and teaching courses.
AMA: California Issuance Commissioner Takes Right Approach to Protect State from Anthem-Cigna and Aetna-Humana Mergers
Statement attributed to Andrew W, Gurman, President, American Medical Association
“The American Medical Association applauds California Insurance Commissioner Dave Jones for taking a strong stand to prevent a near total collapse of competition in the state’s health insurance market. He has taken the right approach to protect California by opposing the Anthem-Cigna and Aetna-Humana mergers.
“The AMA agrees with Commissioner Jones that the mergers would very likely raise premiums above competitive levels and reduce the quality of health care. He was also right in finding that any efficiency savings achieved in the mergers would not likely be passed along to patients. His finding is supported by economic studies suggesting that health insurance companies use monopoly power gained from mergers to charge higher prices for health insurance.
Congressmen Kind, Young Issue Letters of Support for Pharmacists’ Legislation
WASHINGTON, DC – Representatives Todd Yong (R-IN) and Ron Kind (D-WI) issued statements this week to the United States House of Representatives’ Ways and Means Subcommittee on Health in support of pharmacists having a larger role in health care as part of a hearing on legislation to improve and sustain the Medicare program. read more
Study: Gum Disease May Increase Lung Cancer Risk
An analysis of existing research reveals possible link between periodontal disease and the leading cause of cancer death
Chicago (June 23, 2016) —Chinese researchers have found that individuals with periodontal disease—also known as gum disease—might be at an increased risk of developing lung cancer. The report, published ahead-of-print in the Journal of Periodontology , found that individuals with periodontal disease have a 1.24-fold increased risk of developing lung cancer.
In the report, titled “Periodontal Disease and Incident Lung Cancer Risk: A Meta-Analysis of Cohort Studies,” the authors assess the findings of five cohort studies that evaluated 321,420 participants. The analysis notes an increased risk even after adjusting for participants’ alcohol consumption and smoking habits, both of which are common risk factors for periodontal disease. Study participants who were drinkers, smokers, and had been diagnosed with diabetes—which is an independent risk factor for both lung cancer and periodontal disease—demonstrated a 1.36-fold increase in lung cancer risk.
Quintiles Introduces Continuous Glucose Monitoring Services to Improve Diabetes Outcomes
DUBLIN , June 23, 2016 /PRNewswire/ — Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced the U.S. Food and Drug Administration ( FDA ) has approved the company’s supplemental New Drug Application (sNDA) to update the label for AVYCAZ® (ceftazidime and avibactam) with clinical data from a Phase 3 trial evaluating the safety and efficacy of AVYCAZ, in combination with metronidazole, for the treatment of complicated intra-abdominal infections (cIAI) caused by designated susceptible microorganisms. The approved label also contains data from a subset of patients in this trial with infections due to ceftazidime-nonsusceptible (CAZ-NS) pathogens, as well as a subset who had pathogens producing certain extended-spectrum beta-lactamases (ESBLs).
PixarBio Corporation Receives Boston Business Journal “2016 Best Places to Work” Just-In-Time For PixarBio’s Public Offering
- Remote monitoring may improve renal patients’ confidence and therapy adherence; patient management and costs.
- Funding and policies for remote monitoring chronically ill patients are emerging based on potential for increased efficiencies and effectiveness.
DEERFIELD, Ill. –(BUSINESS WIRE)–Jun. 23, 2016– A new study conducted by Baxter International Inc. (NYSE: BAX) and published in PLOS ONE indicates healthcare systems in the United Kingdom , Germany , Italy and Spain see value in supporting remote monitoring technology for chronic health conditions, including end-stage renal disease (ESRD). The study indicates remote monitoring may improve access to care, decrease hospitalizations and reduce treatment costs by helping healthcare professionals manage patients’ treatments and improve adherence.
”Increasing healthcare costs and a growing number of chronically ill patients are driving the need for more affordable and innovative options, like remote monitoring that may support better delivery of home healthcare,” said Giuseppe Accogli , president, Renal, Baxter. ”Baxter conducted this study to better understand the perceived multi-faceted value of remote monitoring, and the continued need for supportive funding and policies that may enable more patients to have access to the new technology.”
Baxter has launched AMIA Automated Peritoneal Dialysis (APD) system with SHARESOURCE, a cloud-based, two-way remote connectivity platform that enables remote patient management in the United States , and the HOMECHOICE CLARIA APD system with SHARESOURCE in Europe . SHARESOURCE is designed to provide more timely therapy decisions by enabling healthcare professionals to deliver individualized dialysis care and allowing on-demand access to treatment data while the patient is at home.